Basic examination of the electrochemiluminescence immunoassay (ECLIA) method for measuring everolimus blood concentrations

DOI

Bibliographic Information

Other Title
  • 電気化学発光免疫測定法によるエベロリムス血中濃度測定試薬“エクルーシス<sup>®</sup>試薬エベロリムス”の基礎的検討

Search this article

Abstract

<p>As the mammalian (mechanistic) target of rapamycin (mTOR) inhibitors, everolimus is an immunosuppressive agent to be used in transplantation. The therapeutic drug monitoring (TDM) of everolimus is essential to prevent acute cellular rejection and to limit toxicity. For therapeutic drug monitoring, pre-everolimus dosing concentrations are measured in whole blood mainly by liquid chromatography tandem mass spectrometry (LC-MS/MS). However, LC-MS/MS for everolimus TDM is not widely used in hospitals owing to either a lack of mass spectrometry instrumentation or resources for assay development. Recently, an everolimus reagent kit for latex particle-enhanced turbidimetric immunoassay (LTIA) has been developed. However, the everolimus concentrations measured by LTIA were lower than those determined by LC-MS/MS. We evaluated the measurement performance of a new everolimus reagent kit by electrochemiluminescence immunoassay (ECLIA). Within-run and day-to-day run reproducibilities were satisfactory. The correlation between values of LTIA and ECLIA was y = 1.24x + 1.48 (r = 0.854). In conclusion, the measurement of everolimus concentration by ECLIA has been proven satisfactory as it provides reliable results for the TDM of everolimus.</p>

Journal

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top